Accelerated Resolution Therapy for Early Maladaptive Grief
2 other identifiers
interventional
440
1 country
4
Brief Summary
The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2023
Longer than P75 for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 15, 2022
CompletedFirst Posted
Study publicly available on registry
November 22, 2022
CompletedStudy Start
First participant enrolled
November 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 14, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 14, 2028
September 25, 2025
September 1, 2025
4.3 years
November 15, 2022
September 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Changes in pre-loss grief
Measured by 14-item self-reported Prolonged Grief-12-Revised (PG-12-R) designed to measure the grief experience of current family caregivers of persons living with progressive disease. Total grief level scores greater than or equal to 30 indicate high levels of pre-loss grief.
Baseline, 4 weeks
Changes in prolonged grief disorder
Measured by 13-item self-reported Prolonged Grief-13-Revised (PG-13-R) designed to assess indicators of pathological grief. Total scores range from 10-50; with score \>29 = prolonged grief.
6 and 13 months post-bereavement
Changes in clinical measure of prolonged grief disorder
Measured by 31-item Structured Clinical Interview for Prolonged Grief Disorder (SCI-P) administered by healthcare professional. Higher scores = higher complicated grief symptoms.
6 and 13 months post-bereavement
Other Outcomes (9)
Change in depression
Baseline, 4 weeks, 6 and 13 months post-bereavement
Caregiver burden
Baseline
Change in perceived stress
Baseline, 6 and 13 months post-bereavement
- +6 more other outcomes
Study Arms (2)
Accelerated Resolution Therapy Group
EXPERIMENTALPrimary caregivers of an immediate family member enrolled in a hospice or palliative care program will receive 4 weekly sessions of accelerated resolution therapy (ART)
Information and Support Group
ACTIVE COMPARATORPrimary caregivers of an immediate family member enrolled in a hospice or palliative care program will receive four-time and attention matched sessions of a standardized social work intervention consisting of information and provision of emotional support.
Interventions
A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.
4 sessions of a standardized social work intervention. Standard of care including education and active listening.
Eligibility Criteria
You may qualify if:
- Primary caregiver of immediate family member who has a life expectancy of less than 12 months
- Score of 30 or higher on the PG-12-R, indicating clinically significant pre-loss grief
- Denial of suicidal ideation or intent, with no evidence of psychotic behavior.
You may not qualify if:
- Since becoming a family caregiver (FCG), they have engaged in another trauma based psychotherapeutic regimen (EMDR, prolonged exposure therapy, trauma focused cognitive behavioral therapy) that could influence response to accelerated resolution therapy (ART).
- Self-reported or clinically assessed major psychiatric disorder (e.g., bipolar disorder, schizophrenia).
- Score of \> 2 on the adapted CAGE questionnaire indicating alcohol /drug dependence.
- Cognitive impairment (SPMSQ \> 4 errors).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
- National Institute on Aging (NIA)collaborator
Study Sites (4)
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
Suncoast Hospice
Clearwater, Florida, 33760, United States
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cindy Tofthagen, PhD
Mayo Clinic
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 15, 2022
First Posted
November 22, 2022
Study Start
November 17, 2023
Primary Completion (Estimated)
March 14, 2028
Study Completion (Estimated)
March 14, 2028
Last Updated
September 25, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share